Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Afuresertib: Phase I/II data

Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE